Eucrisa (crisaborole) ointment, 2%, is now approved for the treatment of mild to moderate atopic dermatitis in pediatric patients as young as 3 months old. Previously, the topical treatment had only been approved for patients 2 years of age and older.
Crisaborole ointment is a nonsteroidal, topical phosphodiesterase 4 (PDE-4) inhibitor. Approval in younger patients was based on data from the phase 4 CrisADe CARE 1 trial, which evaluated the safety and efficacy of crisaborole ointment 2% in 137 patients aged 3 months to less than 24 months with mild to moderate atopic dermatitis involving at least 5% treatable body surface area (BSA), excluding the scalp.
Findings from the study revealed the treatment was well tolerated and demonstrated effectiveness in this patient population. Moreover, the safety profile was similar to that seen in previous clinical trials. The most common adverse reaction associated with therapy includes application site pain, such as burning or stinging.
“Families often spend hours each day attempting to ease their child’s eczema symptoms, affecting both infants and caregivers,” said Lawrence Eichenfield, MD, chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego, vice chair of the Department of Dermatology, and a professor of Dermatology and Pediatrics at UC San Diego School of Medicine. “The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients.”
Eucrisa ointment is supplied in 60g and 100g tubes.
For more information visit pfizer.com.